None listed
Conditions
Brief summary
Strawberry birthmark (haemangioma) grows rapidly during infancy before gradually shrinking in later childhood. Rapidly growing haemangiomas can cause significant disfigurement and functional problems including threatened vision and life. The child affected by problematic growing haemangioma is considered for this study because we believe that Captopril, given in small doses could dramatically shrink the birthmark such that surgery and/or laser therapy would not be needed later on. Captopril has been used in infants and children with high blood pressure for many years. Our research suggests that Capopril will specifically target a particular type of cells in the haemangioma that are responsible for its rapid growth. In this study, we would start the child on small doses of Captopril, given by mouth. The medication is maintained until the birthmark is fully regressed or until 12 months of age
Interventions
Captopril oral solution titrated gradually to a maximum dose of 0.6mg/kg/day in 3 divided doses. With a starting dose of 0.15mg/kg/day in 3 divided doses until the child is 1 year of age.
Sponsors
Hutt Valley District Health Board
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
9 Weeks to 5 Years
Healthy volunteers
No
Inclusion criteria
: Infants and young children with growing problematic haemangiomas whose parents or guardians are willing, able, and competent to administer prescribed medications. (Problematic haemangiomas are defined in the literature as those that cause disruption to form/function of a child or that ulcerate)
Exclusion criteria
Parents and guardians who would not consent to participate in this study. Neonates Infants or children who have underlying cardiovascular disease
Outcome results
None listed